Abstract 608P
Background
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal surfaces. While MMs are distinct from cutaneous melanomas (CMs) in pathogenesis, etiology and prognosis, management of both subtypes has remained largely similar, as the rarity of the disease poses a challenge to developing evidence-based clinical guidelines for MM. We performed a meta-analysis on the use of immune checkpoint inhibitors (ICIs) and targeted therapy for MM.
Methods
We searched five databases (PubMed, Cochrane, Embase, Web of Science and Google Scholar) for studies evaluating the efficacy of ICIs and targeted therapy in the treatment of locally advanced or metastatic MMs. After including only cohort and observational studies with available overall survival (OS) and progression free survival (PFS) data, the eligible studies comprised patients treated with anti-PD1, anti-CTLA4, VEGFR inhibitors or tyrosine kinase inhibitors (TKIs). For single-arm and double-arm studies that reported Kaplan-Meier curves, we digitally reconstructed individual patient data using Guyot's algorithm and calculated the OS, PFS and hazard ratios, along with the 95% confidence intervals.
Results
We included 26 studies with a total of 1911 participants. Our results show that combined anti-PD1 and anti-CTLA4 therapy had the highest 12-month OS and 12-month PFS at 0.677 (0.608,0.754) and 0.388 (0.316,0.475) respectively. This was followed by anti-PD1 therapy alone (OS: 0.602 (0.569,0.638); PFS: 0.282 (0.251,0.317)), anti-PD1 and VEGFR inhibitor combination therapy (OS: 0.506 (0.437,0.585)), TKI therapy (OS: 0.482 (0.376,0.618); PFS: 0.083 (0.037,0.187)) and anti-CTLA4 therapy alone (OS: 0.333 (0.284,0.391); PFS: 0.098 (0.059,0.165)). In the double-arm studies, anti-PD1 and anti-CTLA4 combination therapy had similar OS and PFS with anti-PD1 treatment alone (OS: HR 0.866 (0.616,1.22); PFS: HR 0.848 (0.666,1.08)), however, anti-PD1 therapy alone had significantly better PFS than anti-CTLA4 alone (HR 0.548 (0.376,0.799)).
Conclusions
Collectively, these results demonstrate that anti-PD1 and anti-CTLA4 combination therapy has the most favorable outcome in the treatment of MM, while anti-PD1 therapy is the single best agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract